Literature DB >> 25288090

Triazole-based compound as a candidate to develop novel medicines to treat toxoplasmosis.

Katarzyna Dzitko1, Agata Paneth2, Tomasz Plech3, Jakub Pawełczyk4, Lidia Węglińska3, Piotr Paneth5.   

Abstract

This article reports anti-Toxoplasma gondii activity of 3-(thiophen-2-yl)-1,2,4-triazole-5-thione. The compound displayed significant and reproducible antiparasitic effects at nontoxic concentrations for the host cells, with an experimentally determined 50% inhibitory concentration (IC50) at least 30 times better than that of the known chemotherapeutic agent sulfadiazine. Purine nucleoside phosphorylase was defined as the probable target for anti-Toxoplasma activity of the tested compound. These results provide the foundation for future work to develop a new class of medicines to better treat toxoplasmosis.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25288090      PMCID： PMC4249526          DOI： 10.1128/AAC.03832-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase.

Authors:  Young Ah Kim; Ravindra K Rawal; Jakyung Yoo; Ashoke Sharon; Ashok K Jha; Chung K Chu; Reem H Rais; Omar N Al Safarjalani; Fardos N M Naguib; Mahmoud H El Kouni
Journal:  Bioorg Med Chem       Date:  2010-04-08       Impact factor: 3.641

2.  Benzimidazole-4,7-diones as inhibitors of protozoal (Toxoplasma gondii) purine nucleoside phosphorylase.

Authors:  Frédéric Alvarez; Arnaud Ghérardi; Pascal Nebois; Marie Elizabeth Sarciron; Anne Françoise Pétavy; Nadia Walchshofer
Journal:  Bioorg Med Chem Lett       Date:  2002-03-25       Impact factor: 2.823

3.  Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase.

Authors:  Valeria S Rosso; Sergio H Szajnman; Leena Malayil; Melina Galizzi; Silvia N J Moreno; Roberto Docampo; Juan B Rodriguez
Journal:  Bioorg Med Chem       Date:  2011-04-01       Impact factor: 3.641

4.  Tryptanthrin derivatives as Toxoplasma gondii inhibitors--structure-activity-relationship of the 6-position.

Authors:  Bogdana Krivogorsky; Amber C Nelson; Kelsi A Douglas; Peter Grundt
Journal:  Bioorg Med Chem Lett       Date:  2012-12-20       Impact factor: 2.823

5.  Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.

Authors:  Gang Cheng; Stephen P Muench; Ying Zhou; Gustavo A Afanador; Ernest J Mui; Alina Fomovska; Bo Shiun Lai; Sean T Prigge; Stuart Woods; Craig W Roberts; Mark R Hickman; Patty J Lee; Susan E Leed; Jennifer M Auschwitz; David W Rice; Rima McLeod
Journal:  Bioorg Med Chem Lett       Date:  2013-02-13       Impact factor: 2.823

6.  Expression, characterization and inhibition of Toxoplasma gondii 1-deoxy-D-xylulose-5-phosphate reductoisomerase.

Authors:  Guobin Cai; Lisheng Deng; Jian Xue; Silvia N J Moreno; Boris Striepen; Yongcheng Song
Journal:  Bioorg Med Chem Lett       Date:  2013-01-30       Impact factor: 2.823

7.  Induction of sulfadiazine resistance in vitro in Toxoplasma gondii.

Authors:  C Doliwa; S Escotte-Binet; D Aubert; F Velard; A Schmid; R Geers; I Villena
Journal:  Exp Parasitol       Date:  2012-12-01       Impact factor: 2.011

Review 8.  Antibiotics for human toxoplasmosis: a systematic review of randomized trials.

Authors:  Senaka Rajapakse; Mitrakrishnan Chrishan Shivanthan; Nilakshi Samaranayake; Chaturaka Rodrigo; Sumadhya Deepika Fernando
Journal:  Pathog Glob Health       Date:  2013-06       Impact factor: 2.894

Review 9.  NIH conference. Recent advances in the management of AIDS-related opportunistic infections.

Authors:  H C Lane; B E Laughon; J Falloon; J A Kovacs; R T Davey; M A Polis; H Masur
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

10.  1,4-Disubstituted thiosemicarbazide derivatives are potent inhibitors of Toxoplasma gondii proliferation.

Authors:  Katarzyna Dzitko; Agata Paneth; Tomasz Plech; Jakub Pawełczyk; Paweł Stączek; Joanna Stefańska; Piotr Paneth
Journal:  Molecules       Date:  2014-07-09       Impact factor: 4.411
View more
  9 in total

1.  Imidazole derivatives as antiparasitic agents and use of molecular modeling to investigate the structure-activity relationship.

Authors:  Oluyomi Stephen Adeyemi; Abiodun Omokehinde Eseola; Winfried Plass; Olubunmi Atolani; Tatsuki Sugi; Yongmei Han; Gaber El-Saber Batiha; Kentaro Kato; Oluwakemi Josephine Awakan; Tomilola Debby Olaolu; Charles Obiora Nwonuma; Omokolade Alejolowo; Akinyomade Owolabi; Damilare Rotimi; Omowumi Titilola Kayode
Journal:  Parasitol Res       Date:  2020-04-11       Impact factor: 2.289

2.  Phytoecdysteroids as modulators of the Toxoplasma gondii growth rate in human and mouse cells.

Authors:  Katarzyna Dzitko; Marcin Mikołaj Grzybowski; Jakub Pawełczyk; Bożena Dziadek; Justyna Gatkowska; Paweł Stączek; Henryka Długońska
Journal:  Parasit Vectors       Date:  2015-08-15       Impact factor: 3.876

3.  Characterization of Toxoplasma gondii glyoxalase 1 and evaluation of inhibitory effects of curcumin on the enzyme and parasite cultures.

Authors:  Youn-Kyoung Goo; Junya Yamagishi; Akio Ueno; Mohamad Alaa Terkawi; Gabriel Oluga Aboge; Dongmi Kwak; Yeonchul Hong; Dong-Il Chung; Makoto Igarashi; Yoshifumi Nishikawa; Xuenan Xuan
Journal:  Parasit Vectors       Date:  2015-12-23       Impact factor: 3.876

Review 4.  A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).

Authors:  Mahbobeh Montazeri; Mehdi Sharif; Shahabeddin Sarvi; Saeed Mehrzadi; Ehsan Ahmadpour; Ahmad Daryani
Journal:  Front Microbiol       Date:  2017-01-20       Impact factor: 5.640

Review 5.  Drugs in development for toxoplasmosis: advances, challenges, and current status.

Authors:  P Holland Alday; Joseph Stone Doggett
Journal:  Drug Des Devel Ther       Date:  2017-01-25       Impact factor: 4.162

6.  Synthesis and biological evaluation of ursolic acid derivatives bearing triazole moieties as potential anti-Toxoplasma gondii agents.

Authors:  Tian Luan; Chunmei Jin; Chun-Mei Jin; Guo-Hua Gong; Zhe-Shan Quan
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

7.  Synthesis and anti-Toxoplasma activity of indole-triazole compounds on tachyzoites of RH strain.

Authors:  Mohammad Saleh Bahreini; Aida Iraji; Najmeh Edraki; Ali Arab Monfared; Qasem Asgari
Journal:  Ann Med Surg (Lond)       Date:  2022-01-08

8.  Inhibition of Toxoplasma gondii by 1,2,4-triazole-based compounds: marked improvement in selectivity relative to the standard therapy pyrimethamine and sulfadiazine.

Authors:  Lidia Węglińska; Adrian Bekier; Nazar Trotsko; Barbara Kaproń; Tomasz Plech; Katarzyna Dzitko; Agata Paneth
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

9.  Docking and QSAR of Aminothioureas at the SARS-CoV-2 S-Protein-Human ACE2 Receptor Interface.

Authors:  Wojciech Płonka; Agata Paneth; Piotr Paneth
Journal:  Molecules       Date:  2020-10-12       Impact factor: 4.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.